Dallas, TX – According to filings with the U.S. Securities and Exchange Commission, Instil Bio is raising $25,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Bronson Crouch played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Instil Bio

Instil Bio is a cell therapy company developing tumor infiltrating lymphocytes (TIL) for the treatment of solid tumor cancers. TIL are a patient’s own T cells harvested from the patient’s tumor, which are then expanded and reinfused into the patient to target and kill cancer cells. The company is advancing its proprietary manufacturing expertise, technology, and data into clinical trials, including a planned registrational study with its lead candidate and a first-in-human study of its next-generation engineered TIL. The company is led by world-class cell therapy experts and backed by premier global institutional investors. Instil is located in the greater Los Angeles area with additional manufacturing and research facilities in Manchester, UK.

To learn more about Instil Bio, visit http://instilbio.com/

Contact:
Bronson Crouch, Chief Executive Officer
240-676-3715
https://www.linkedin.com/in/bronson1/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved